A Gap in Standard Care
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer. When it's locally advanced — meaning it has grown beyond the original site but hasn't spread to distant organs — the standard treatment combines radiation with chemotherapy given at the same time. This concurrent approach is aggressive and effective, but it's also hard on the body.
Many patients — especially older adults, those with heart or lung disease, or those weakened by the cancer itself — simply cannot tolerate concurrent chemo-radiation. For them, options have been limited. Some receive radiation alone, which has historically shown modest results.
A Different Kind of Radiation
Traditional radiation spreads doses over many weeks, hitting the tumor from one or two angles. SABR — stereotactic ablative radiotherapy — works differently. Think of it like a magnifying glass focusing sunlight. Instead of spreading the energy broadly, SABR targets the tumor from many angles simultaneously, delivering very high doses with extreme precision.
This precision means surrounding healthy tissue gets far less radiation. The tumor, however, gets hit hard. The technique has already proven effective in early-stage lung cancer. The question this trial asked was: can it also work in locally advanced disease in patients who can't handle chemotherapy?
The START-NEW-ERA Phase 2 trial enrolled 50 patients with unresectable (inoperable) locally advanced NSCLC who were not candidates for standard concurrent chemo-radiation. Each received SABR targeting both the primary tumor and affected lymph nodes, guided by detailed PET-CT imaging. The median radiation dose was 45 Gray (a unit of radiation) to the main tumor in 5 daily sessions. Researchers followed patients for a median of 6 years — a notably long follow-up for this type of study.
The headline result: 46% of patients were alive at five years. That may sound modest, but consider the context — these were patients with advanced, inoperable disease who couldn't receive the best available standard treatment. The three-year overall survival was 70%, suggesting a meaningful portion of patients lived well beyond what might have been expected.
Local control was also strong: 64% of patients were free from local tumor recurrence at both three and five years. And critically, no patients developed severe late side effects (Grade 3 or higher toxicity). For a population already dealing with serious illness, avoiding major treatment-related harm is a significant outcome.
These results don't mean SABR works for every advanced lung cancer patient — but for those who can't do chemo, the data is encouraging.
Not Everyone Responded the Same Way
The data also revealed important patterns. Patients whose tumors were squamous cell carcinoma (a specific subtype) and those who received lower radiation doses (below 40 Gray) were more likely to have local recurrence. Tumors that came back were consistently located in central or ultracentral positions in the chest — meaning they were near major airways and blood vessels, where delivering very high doses is technically harder.
What Researchers in This Area Are Saying
This trial adds to a growing body of evidence that SABR can serve as a meaningful treatment option for patients who fall outside standard protocols. The focus on exactly where recurrences happened — whether inside or outside the treated area — gives radiation oncologists valuable information for planning future treatments and refining dose strategies. The consistent finding that higher doses correlate with better local control has already influenced how some centers approach similar patients.
If you or a family member has locally advanced lung cancer and has been told they are not a candidate for standard chemotherapy plus radiation, it may be worth asking a radiation oncologist specifically about SABR or stereotactic radiotherapy. Not every center offers this technique for locally advanced disease, and patient selection matters. This approach is not appropriate for all tumor locations or stages, but for the right patient, it represents a real treatment path.
Limitations to Understand
This was a non-randomized Phase 2 trial with only 50 patients — a small group. There was no comparison arm of patients receiving a different treatment, which makes it harder to be certain the outcomes were due to SABR specifically. The findings need confirmation in larger, randomized trials before SABR becomes a standard recommendation for this patient group.
The results from START-NEW-ERA contribute to the evidence base that will eventually inform clinical guidelines for patients with locally advanced NSCLC who are unfit for chemotherapy. Researchers will likely pursue larger randomized trials comparing SABR to other treatment options in this population. The field is also exploring whether combining SABR with immunotherapy — a newer class of cancer treatment — might further improve outcomes. That work is already underway at multiple institutions.
